Study S000626

A Trial Comparing Exposure of Semaglutide When Dosing New Formulations of Oral Semaglutide to Healthy Male Subjects

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT03638778
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: COMPLETED
Enrollment: 105
Start: 2018-08-17
Primary completion: 2018-12-05
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:Semaglutide 3 mg; DRUG:Semaglutide 7 mg; DRUG:Semaglutide B 3 mg; DRUG:Semaglutide B 7 mg; DRUG:Semaglutide C 3 mg; DRUG:Semaglutide C 7 mg; DRUG:Semaglutide D 3 mg; DRUG:Semaglutide D 7 mg
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1206-6210; REGISTRY:2017-005023-24; NIH:2017

Registered primary outcomes

AUC0-24h,sema,day10, area under the semaglutide plasma concentration time curve from 0 to 24 hours after the 10th dosing [0 to 24 hours on day 10]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.